Abstract
Adenocarcinoma of the prostate is the most common cancer in men. The majority of cancers are discovered once they have already metastasized, and there is no effective therapy for prostatic cancer at this stage. The use of cytokine-secreting tumor cell preparations as therapeutic vaccines for the treatment of advanced prostate cancer was investigated in the Dunning rat R3327-MatLyLu prostatic tumor model, IL-2 secreting, irradiated, tumor cell preparations were capable of curing animals with s.c. established tumors, and induced immunological memory that protected animals from subsequent tumor challenge. Immunotherapy was less effective when tumors were induced orthotopically, but nevertheless led to improved outcome, significantly delaying, and occasionally preventing, recurrence of tumors after resection of the cancerous prostate. Granulocyte-macrophage colony stimulating factor secreting tumor cell preparations were less effective, and interferon-γ secreting cells had only a marginal effect. Induction of a potent immune response in tumor bearing animals against the nonimmunogenic MatLyLu tumor supports the view that active immunotherapy warrants further investigation as a potential therapeutic approach to prostate cancer.
| Original language | English |
|---|---|
| Pages (from-to) | 1760-1765 |
| Number of pages | 6 |
| Journal | Cancer Research |
| Volume | 54 |
| Issue number | 7 |
| State | Published - Apr 1 1994 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Immunotherapy of prostate cancer in the dunning rat model : Use of cytokine gene modified tumor vaccines. / Vieweg, Johannes; Rosenthal, Felicia M.; Bannerji, Rajat; Heston, Warren D W; Fair, William R.; Gilboa, Eli; Gilboa, Eli.
In: Cancer Research, Vol. 54, No. 7, 01.04.1994, p. 1760-1765.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Immunotherapy of prostate cancer in the dunning rat model
T2 - Use of cytokine gene modified tumor vaccines
AU - Vieweg, Johannes
AU - Rosenthal, Felicia M.
AU - Bannerji, Rajat
AU - Heston, Warren D W
AU - Fair, William R.
AU - Gilboa, Eli
AU - Gilboa, Eli
PY - 1994/4/1
Y1 - 1994/4/1
N2 - Adenocarcinoma of the prostate is the most common cancer in men. The majority of cancers are discovered once they have already metastasized, and there is no effective therapy for prostatic cancer at this stage. The use of cytokine-secreting tumor cell preparations as therapeutic vaccines for the treatment of advanced prostate cancer was investigated in the Dunning rat R3327-MatLyLu prostatic tumor model, IL-2 secreting, irradiated, tumor cell preparations were capable of curing animals with s.c. established tumors, and induced immunological memory that protected animals from subsequent tumor challenge. Immunotherapy was less effective when tumors were induced orthotopically, but nevertheless led to improved outcome, significantly delaying, and occasionally preventing, recurrence of tumors after resection of the cancerous prostate. Granulocyte-macrophage colony stimulating factor secreting tumor cell preparations were less effective, and interferon-γ secreting cells had only a marginal effect. Induction of a potent immune response in tumor bearing animals against the nonimmunogenic MatLyLu tumor supports the view that active immunotherapy warrants further investigation as a potential therapeutic approach to prostate cancer.
AB - Adenocarcinoma of the prostate is the most common cancer in men. The majority of cancers are discovered once they have already metastasized, and there is no effective therapy for prostatic cancer at this stage. The use of cytokine-secreting tumor cell preparations as therapeutic vaccines for the treatment of advanced prostate cancer was investigated in the Dunning rat R3327-MatLyLu prostatic tumor model, IL-2 secreting, irradiated, tumor cell preparations were capable of curing animals with s.c. established tumors, and induced immunological memory that protected animals from subsequent tumor challenge. Immunotherapy was less effective when tumors were induced orthotopically, but nevertheless led to improved outcome, significantly delaying, and occasionally preventing, recurrence of tumors after resection of the cancerous prostate. Granulocyte-macrophage colony stimulating factor secreting tumor cell preparations were less effective, and interferon-γ secreting cells had only a marginal effect. Induction of a potent immune response in tumor bearing animals against the nonimmunogenic MatLyLu tumor supports the view that active immunotherapy warrants further investigation as a potential therapeutic approach to prostate cancer.
UR - http://www.scopus.com/inward/record.url?scp=0028297315&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028297315&partnerID=8YFLogxK
M3 - Article
C2 - 8137291
AN - SCOPUS:0028297315
VL - 54
SP - 1760
EP - 1765
JO - Journal of Cancer Research
JF - Journal of Cancer Research
SN - 0099-7013
IS - 7
ER -